基于网络平台的生物标志物预测模型指导类风湿关节炎生物治疗的多中心随机对照试验方案
PREDIRA试验为前瞻性III期多中心随机单盲对照研究,纳入抗TNF治疗失败的类风湿关节炎患者,比较使用SinnoTest®蛋白组学预测软件选择生物制剂与常规实践选择生物制剂的临床和药物经济学影响,主要分析6个月治疗后的结局。
要点
- PREDIRA试验评估SinnoTest®预测软件指导生物制剂选择的临床与药物经济学价值。
- 研究对象为抗TNF治疗失败的类风湿关节炎患者,干预组用预测软件选择利妥昔单抗、阿达木单抗或阿巴西普。
- 主要分析6个月治疗后的临床和药物经济学影响。
核心结论
- 该试验将是首个生物治疗反应预测软件的验证研究,有望将个性化医疗引入类风湿关节炎管理。
研究设计与样本
- 前瞻性、III期、对照、多中心、随机、单盲(患者)临床试验。
- 纳入既往抗TNF治疗失败的类风湿关节炎患者。
- 干预组使用基于蛋白组学生物标志物的SinnoTest®软件处方生物制剂(利妥昔单抗、阿达木单抗、阿巴西普),对照组按常规实践处方生物制剂(任何生物制剂)。
- 试验内嵌套子研究,建立生物样本库并分析患者蛋白组学特征及其在研究期间的改变。
主要发现
- 原文未报告本研究结果;背景提及约40%患者对合成DMARD一线治疗反应不足,约三分之一接受生物治疗者对所选用药物无反应。
关键数值与推荐
- 主要目标是分析治疗6个月后的临床和药物经济学影响。
临床怎么用
- 若验证成功,SinnoTest®软件可辅助抗TNF治疗失败的类风湿关节炎患者选择生物制剂,减少经验性换药。
局限性
- 本文为试验方案,尚无结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available. METHODS: The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study. DISCUSSION: This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System. TRIAL REGISTRATION: ClincalTrials.gov NCT04147026 . Registered on 31 October, 2019.
引用
- Freites-Núñez D, Baillet A, Rodriguez-Rodriguez L, et al. Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA). Trials. 2020. PMID: 32867830. doi:10.1186/s13063-020-04683-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。